FDA 483 - AGC Biologics, Inc.

CMC ICOS Biologics, Inc. in Bothell, Washington, was inspected by the FDA, revealing significant deficiencies in their manufacturing processes. The inspection found incomplete process validation, inadequate investigation of production deviations, and failures in performing preventative maintenance and following deviation management procedures. These issues indicate a lack of control over critical manufacturing operations.